Combining mitochondrial proteomes and Mendelian randomization to identify novel therapeutic targets for diabetic nephropathy DOI Creative Commons
Yang Liu, Rong Wu, Zhenlei Zhou

et al.

Renal Failure, Journal Year: 2025, Volume and Issue: 47(1)

Published: March 24, 2025

Diabetic nephropathy (DN) is a common microvascular complication of diabetes. Mitochondrial dysfunction in the kidney caused by diabetes has previously been linked to pathogenesis DN. By mass spectrometry, we identified characteristic proteins DN from renal mitochondria mouse model. To identify core among them, Mendelian randomization (MR) analysis, microarray data validation, and drug-target interaction analysis were employed. MR found that 189 candidate targets had causal link with risk factors (estimated glomerular filtration rate (eGFR), urinary albumin excretion, serum creatinine). After systematic validated SLC25A16, CTNND1, C2CD2L, ALDH3A2, NEU1, APEH, CORO1A, NUDT19, NDUFA4L2 are promising druggability This study suggests feasibility using for drug target screening, provides potential insights into mitochondrial research, which may contribute further exploration.

Language: Английский

Combining mitochondrial proteomes and Mendelian randomization to identify novel therapeutic targets for diabetic nephropathy DOI Creative Commons
Yang Liu, Rong Wu, Zhenlei Zhou

et al.

Renal Failure, Journal Year: 2025, Volume and Issue: 47(1)

Published: March 24, 2025

Diabetic nephropathy (DN) is a common microvascular complication of diabetes. Mitochondrial dysfunction in the kidney caused by diabetes has previously been linked to pathogenesis DN. By mass spectrometry, we identified characteristic proteins DN from renal mitochondria mouse model. To identify core among them, Mendelian randomization (MR) analysis, microarray data validation, and drug-target interaction analysis were employed. MR found that 189 candidate targets had causal link with risk factors (estimated glomerular filtration rate (eGFR), urinary albumin excretion, serum creatinine). After systematic validated SLC25A16, CTNND1, C2CD2L, ALDH3A2, NEU1, APEH, CORO1A, NUDT19, NDUFA4L2 are promising druggability This study suggests feasibility using for drug target screening, provides potential insights into mitochondrial research, which may contribute further exploration.

Language: Английский

Citations

0